A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

NCT07105111 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia
Schizoaffective Disorder
Bipolar Disorder
Major Depressive Disorder
Tardive Dyskinesia

Interventions

DRUG: Valbenazine

Sponsor

Neurocrine Biosciences